QART Medical, a Male Fertility Company, Discloses Recent Financing

March 5th, Raanana, Israel – Chartered-Opus investment managers was joined by Eastern Epic Capitals, a Singapore based venture capital fund which focuses on frontier technologies to create value and make the world a better place, led an extension of a Series A round of financing, as well as additional angel investment.

“We are happy to have Eastern EPIC Capitals join the long-standing commitment of QART investors at this very exciting inflection point in QART. Our flagship product, Q300™, is the first and only highly informative companion for male fertility treatments. Q300™ is now FDA, CE-Mark and AMAR (Israeli MoH) cleared for marketing, and we’ve started a multi-center clinical study to look at real-life aspects of its use, such as improvement in the clinical indicators of clinical success”, said Alon Shalev, CEO and Co-founder of QART Medical.

Dr Mitch Rosen, MD, an expert in reproductive endocrinology and fertility and the director of the UCSF Fertility Preservation Program, where QART’s Q300 system is now being evaluated “As counter intuitive as it may sound, only sperm matters. I mean, oocytes are vital, but scarce. In each retrieval we typically withdraw half a dozen, up to a dozen of them… therefore we’re going to try and create embryos from all of them. With sperm cells, you could have hundreds of millions of those with likely unequal developmental capacity. They are tiny, transparent, they’re in motion, and they rotate and go in and out of focus. QART’s system and technology may revolutionize the selection process to capture the ideal sperm cell to enhance the chances of successful fertilization and pregnancy.”


About QART Medical QART Medical is an ISO13485 certified MedTech company addressing the global infertility epidemic. To do so, QART has developed the Q300™, a breakthrough solution to male infertility issues that provides a quantitative characterization of sperm cell morphology to facilitate informed clinical decision making when selecting cells for use in in-vitro fertilization (IVF). QART aims to improve current success rates of Intra-Cytoplasmic Sperm Injection (ICSI) by quantitatively characterizing the morphology and composition of individual sperm cells with 3D imaging. The Q300™ is registered with the US FDA, has received Israeli regulatory registration for commercial sales, and bears the CE (Conformité Européenne) Mark.